is retatrutide bad 10 Mistakes You Must Avoid on (ruins it's benefits) Retatrutide, an experimental weight-loss drug,

Market Statistics Key Takeaways By type of GLP-1 agonist drugs, the long-acting GLP-1 agonist segment dominated in 2025

GLP-1 receptor agonists have been shown to reduce major adverse cardiovascular events including cardiovascular death, heart attack, and stroke in patients with type 2 diabetes

Though GLP-1s impact is primarily felt in the downstream part of the value chain, the spillover effects of changed consumer behavior among a small but rapidly growing segment are hitting across the industry in varying degrees: For F&B brands focused on calorie-dense snacks, focus should be on product innovation for better for you lines

Earliest commercial launch Q1Q2 2028

Public clinical trials have monitored adverse events and safety outcomes under controlled protocols